Financing the Plan

Accelerating HIV vaccine research will require a large infusion of new resources. Nearly U.S. $700 million per year is currently spent on HIV vaccine research worldwide. While this represents more than a five-fold increase over the past decade, it still falls nearly halfway short of the U.S. $1.2 billion that is estimated to be needed to overcome the obstacles identified in the Enterprise scientific strategic plan, and ultimately develop an effective vaccine.

The Enterprise calls on governments and other funders of HIV vaccine research to significantly increase their financial commitments, and to target current and new resources to the priority areas in the scientific strategic plan. It is critical that new funders come on board as well, and that private pharmaceutical and biotechnology companies increase their own investments in HIV vaccine research.